Find Academic Supervisors

Yeonhwa Park is a Professor and holder of the Francis Chair in the Department of Food Science at the University of Massachusetts Amherst. Her research focuses on functional foods, bioactive components, and environmental contaminants' effects on obesity and aging. She investigates food bioactives like conjugated linoleic acid (CLA) and environmental pollutants like PFAS to understand their roles in metabolic disorders and aging mechanisms. Her work spans multiple models, including C. elegans, zebrafish, and rodent studies, emphasizing translational applications for human health. Teaching responsibilities include courses such as 'Science of Food' (FS150), 'Biology of Food in Human Health' (FS270), and 'Bioactive Food Components' (FS750). Awards include Clarivate Highly Cited Researcher (2017–2018), Faculty Convocation Award (2015), and the Timothy Mounts Award (2015). Her research has been published in over 150 peer-reviewed articles, with recent emphasis on environmental contaminants' impact on obesity and type 2 diabetes, and the use of C. elegans for screening bioactives. Key findings include CLA's role in fat reduction, PFAS-induced metabolic disruption, and the application of alternative models (e.g., C. elegans) to reduce animal testing. Her lab integrates molecular biology, toxicology, and food science to address global health challenges like the obesity epidemic and environmental toxin exposure.

• Functional Foods
• Obesity
• Environmental Contaminants
• +3 more

Reilly T. Enos, PhD, is an Assistant Professor in the Department of Pathology, Microbiology & Immunology at the University of South Carolina School of Medicine. His research focuses on the molecular mechanisms of sex differences in obesity, particularly metabolic and inflammatory processes influenced by sex steroids. The Enos Lab employs rodent models and advanced metabolic phenotyping to investigate menopause-related metabolic dysfunction and complementary therapies. PhD, Exercise Science (Applied Physiology), University of South Carolina, 2013 Post-Doctoral, Complementary and Alternative Medicine in Cancer and Obesity, University of South Carolina School of Medicine, 2017 MS, Exercise Physiology, Baylor University, 2009 BS, Dietetics, University of Northern Colorado, 2010 BA, Spanish & Physical Education, College of Wooster, 2007 Dr. Enos’s research spans immunometabolism, obesity, cancer cachexia, and gut microbiota. His work explores how dietary components (e.g., quercetin, emodin), hormonal status (especially estrogen), and immune modulation (e.g., miR-155, macrophages) influence metabolic and oncological outcomes. He investigates sex-specific responses to high-fat diets, inflammation, and therapeutic interventions using transgenic and diet-induced mouse models. His recent publications highlight trends in metabolic physiology, inflammation, and cancer, often examining the interplay between adipose tissue, immune cells, and hormonal regulation. Key themes include the impact of vivarium conditions on reproducibility, the role of microRNAs in tumorigenesis, and the safety and efficacy of natural compounds. Dr. Enos has not been awarded any listed scientific prizes or fellowships in the provided texts. He advises a research team focused on metabolic and inflammatory disease models, frequently collaborating with researchers such as Erin A. Murphy and Kandy T. Velázquez. His lab receives funding for studies on obesity, cancer, and complementary medicine, though specific grants are not detailed. The lab is equipped for metabolic phenotyping and rodent model studies. The Enos Lab is dedicated to understanding sex-specific metabolic regulation and developing targeted therapies for obesity and cancer-related metabolic disorders, with a focus on translational relevance and experimental rigor.

• Obesity
• Metabolic Disease
• Sex Differences in Metabolism
• +9 more

Dr. Elahe Alizadeh is an Assistant Professor (Adjunct) at Queen's University and a Research Scientist at the Queen's Centre for Particle Studies (QCPU). She holds a BSc in Applied Physics from Amirkabir University of Technology (Iran), an MSc in Medical-Radiation Physics from the same institution, and a PhD in Nano-Bio-Physics from the University of Innsbruck (Austria). Her career includes a postdoctoral fellowship at Université de Sherbrooke (Canada) and roles at the University of Saskatchewan, where she developed pre-clinical radiopharmaceutical programs and managed advanced imaging facilities. Currently, she oversees nuclear imaging projects using tri-modality µPET/SPECT/CT scanners and maintains radiation safety certifications (RSO-1). Research Focus : Radiation physics, medical imaging, radiobiology, and pre-clinical theranostics Awards : Radiation Research Society Jack Fowler Award (2013) Committees : Canadian Radiation Protection Association (CRPA), Queen’s Radiation Safety Committee Her work bridges radiation safety, imaging technology, and translational medicine. Key research areas include radiation damage mechanisms, targeted cancer therapies, and oxygen-sensing pathways in pulmonary diseases. Recent studies span pulmonary hypertension treatments, PET imaging biomarkers, and plasma-based cancer therapies.

• Radiation Physics
• Medical Imaging
• Radiobiology
• +5 more

Coleen T. Murphy is the James A. Elkins Jr. Professor in the Life Sciences and Professor of Molecular Biology and the Lewis-Sigler Institute for Integrative Genomics at Princeton University. She serves as Director of the Lewis-Sigler Institute and Director of the Paul F. Glenn Laboratories for Aging Research, highlighting her leadership in aging and genomics research. Her work bridges molecular biology, genetics, and computational approaches to understand aging and age-related decline. Her research focuses on the molecular mechanisms of aging, particularly using the nematode C. elegans as a model organism. Key interests include longevity pathways, insulin/IGF-1 signaling, reproductive aging, neurodegenerative diseases, transgenerational inheritance, and mitochondrial function. Her lab integrates genomic, transcriptomic, and functional screening techniques to identify genes and pathways that regulate aging and healthspan. The recent publications of her lab demonstrate a strong trend in interdisciplinary research combining genetics, neuroscience, and computational biology. Themes include cognitive aging, learned behavior, pathogen avoidance, metabolic regulation, and drug discovery in neurodegenerative models. Her work increasingly employs high-throughput methods and cross-omics analysis to uncover conserved mechanisms relevant to human health. HHMI Faculty Scholar, Howard Hughes Medical Institute (2016) Pioneer Award, National Institutes of Health (2015) Innovation Award, Department of Molecular Biology, Princeton University (2014) Glenn Foundation for Medical Research Award (2012) Dr. Murphy leads a vibrant research group and mentors numerous students and postdoctoral researchers. Her lab has secured significant funding from HHMI, NIH, and the Glenn Foundation, supporting innovative projects in aging and longevity. She also directs major research initiatives, including the Simons Foundation’s SCPAB (Plasticity and the Aging Brain), underscoring her national leadership. The Murphy Lab at Princeton is a multidisciplinary team employing C. elegans to study aging, cognitive decline, and intergenerational signaling. The lab utilizes cutting-edge tools including microfluidics (e.g., CeLab), transcriptomics, and behavioral assays. It is part of the Department of Molecular Biology and the Lewis-Sigler Institute, fostering collaboration across genomics, neuroscience, and computational biology.

• Aging
• Molecular Biology
• Genetics & Genomics
• +7 more

Professor Ivan Vujanac is a faculty member at the Faculty of Veterinary Medicine, University of Belgrade , where he serves as a full professor in the Department of Ruminant Diseases . His research focuses on Veterinary Science, Animal Physiology, and Endocrinology , particularly metabolic disorders in dairy cows and trace element supplementation. Key Research Areas: Insulin signaling, chromium supplementation, hypocalcemia, glucocorticoid stress markers, rumen acidosis, and neonatal calf health. Recent Publications highlight studies on hormonal regulation in dairy cows, chromium's metabolic effects, ectoparasite management, and selenium-iodine interactions. Collaborations include researchers like Danijela Kirovski , Radiša Prodanović , and Ljubomir Jovanović . Contact: vujanac@vet.bg.ac.rs

• Veterinary Science
• Animal Physiology
• Endocrinology
• +3 more

Dr. Michael Drozd is an Academic Clinical Lecturer in the School of Medicine at the University of Leeds, part of the Faculty of Medicine and Health. He is affiliated with the Leeds Institute of Cardiovascular and Metabolic Medicine, where he conducts translational research in cardiology with a focus on cardiometabolic diseases and infection. His work bridges clinical practice and scientific investigation, particularly in understanding how metabolic conditions like diabetes influence cardiovascular and infectious disease outcomes. Position: Academic Clinical Lecturer Institution: University of Leeds School: School of Medicine Research Institute: Leeds Institute of Cardiovascular and Metabolic Medicine Email: M.Drozd@leeds.ac.uk Dr. Drozd holds a BSc, MBChB (with honors), and PhD. He is a member of the Royal College of Physicians (MRCP) and the European Society of Cardiology (FESC), reflecting his clinical and academic credentials. His research interests center on cardiometabolic disease and infection , with a strong emphasis on translational approaches. Key areas include: Mechanisms linking diabetes, obesity, and cardiovascular disease Infection-related mortality in metabolic disorders Endothelial signaling in vascular dysfunction Biomarker discovery in heart failure Hypoxia and innate immune training Inflammation as a driver of cardiovascular risk His recent publications, spanning from 2017 to 2025, demonstrate a consistent output in high-impact journals such as Diabetes Care , Cardiovascular Research , The Lancet , and J Infect . These works often utilize large cohort data (e.g., UK Biobank) and molecular techniques to explore causal relationships and novel pathways. A recurring theme is the intersection of metabolic health, immune response, and cardiovascular outcomes. Dr. Drozd is actively involved in medical education, supervising MBChB students and academic foundation doctors, and delivering cardiovascular teaching across multiple years of the medical curriculum. He is also passionate about widening participation in medicine, contributing to equity in medical education. His scientific contributions include: Investigating plasma MERTK as a causal biomarker for infection mortality Identifying novel transcriptomic biomarkers (Erbb3, Hspa2) in diabetic heart failure Elucidating IGF-1 signaling in endothelial barrier function and atherogenesis Mapping comorbidity trajectories in heart failure Exploring mentorship challenges in cardiology training Dr. Drozd collaborates extensively with leading researchers such as Professor Mark T. Kearney, Dr. Ryan M. Cubbon, and Professor Stephen B. Wheatcroft. He is not listed as retired, deceased, or former staff, and there is no indication of part-time status. His ongoing research and teaching activities confirm his active role in academic medicine.

• Cardiology
• Cardiometabolic Disease
• Infection and Immunity
• +7 more

Matthew Gill is an Associate Professor in the Department of Genetics, Cell Biology and Development within the College of Biological Sciences at the University of Minnesota, Twin Cities. He leads the Gill Lab as part of the Masonic Institute on the Biology of Aging and Metabolism and the Medical Discovery Team on Aging, focusing on translational aging research since their 2017 founding. Dr. Gill's research employs C. elegans to dissect fundamental aging mechanisms through genetic, chemical, and biochemical approaches. His lab discovered a novel alternatively spliced insulin receptor (DAF-2B) that acts as a decoy to sequester insulin ligands and modulate aging, alongside identifying an endocannabinoid signaling system in nematodes. Current work investigates DAF-2B's splicing regulation and mammalian conservation, bridging developmental processes like dauer formation with lifespan extension pathways. Analysis of his publication record (2014-2023) reveals consistent focus on insulin signaling dynamics, alternative splicing events, and lipid-based neuromodulation in aging. His work demonstrates how conserved pathways—particularly insulin/IGF-1 signaling and stress responses—can be targeted to influence longevity, with implications for age-related metabolic disorders and neurodegenerative conditions. Scientific Awards: No specific awards were mentioned in the provided sources. Dr. Gill advises PhD students including Tom Hodder (co-advised with Chad Myers), who develops geroprotector screening methods, and mentors postdoctoral researchers like Bryan Martinez studying DAF-2B regulation. His research is institutionally supported through the Masonic Institute and Medical Discovery Team on Aging, indicating sustained funding for mechanistic aging studies. Current grants focus on insulin receptor splicing mechanisms and cross-species conservation of aging pathways. The Gill Lab operates from Nils Hasselmo Hall, leveraging C. elegans genetics to explore therapeutic targets for human aging. Ongoing projects examine how environmental stressors interact with genetic factors to influence aging, with future work directed toward mammalian validation of decoy receptor mechanisms and drug discovery for age-related decline.

• Aging
• Genetics of Aging
• Insulin Signaling
• +5 more

E. Jane Albert Hubbard is a Professor in both the Department of Cell Biology and Department of Pathology at NYU Grossman School of Medicine. She leads the Jane Hubbard Lab, which focuses on understanding how diet and aging affect stem cells using the nematode worm C. elegans as a model organism. Her research examines how the germline stem cell pool responds to genetic and environmental cues, with particular emphasis on conserved signaling pathways including insulin-IGF, TOR, and TGFß. Dr. Hubbard's research interests span multiple disciplines including cancer biology, developmental genetics, computational biology, metabolism, and stem cell biology. Her lab investigates several key areas: DAF-18/PTEN and germ cell quiescence, regulation of germline proliferation and differentiation by environmental factors, germline proliferation during aging, stem cell dynamics through computational modeling, and regulation of germline proliferation by direct cell-cell communication. President of the Genetics Society of America (2022) Active member of GSA Ethics Committee and Public Communication and Engagement Committee Host of the GSA "SNPets" podcast Author of numerous publications on C. elegans germline stem cells Recipient of Damon Runyon Cancer Research Foundation postdoctoral fellowship Dr. Hubbard's lab has trained numerous scientists who have gone on to successful careers in academia and industry. Her approach emphasizes inclusive research environments that welcome scientists regardless of sex, race, ethnicity, sexual orientation, disability, age, religion, country-of-origin, or socioeconomic background. The lab's work has important implications for understanding basic mechanisms of stem cell regulation that may inform cancer research and aging studies.

• cancer
• developmental genetics
• computational biology
• +7 more

L. Ryan Baugh is a Professor of Biology and Associate Professor of Cell Biology at Duke University. He is also an affiliate of the Duke Regeneration Center and the Center for Genomic and Computational Biology. His research focuses on phenotypic plasticity and developmental robustness in response to variable environmental conditions, particularly nutrient availability. Dr. Baugh earned his Ph.D. from Harvard University in 2004 and his B.S. from the University of Georgia in 1997. His educational background provided the foundation for his research in molecular genetics and developmental biology. Dr. Baugh's research program investigates how animals adapt to starvation over different time scales using the roundworm C. elegans as a model organism. His lab employs functional genomics (bulk and single-cell), statistical methods, quantitative genetics, and molecular genetics to address fundamental questions about how gene regulation and development are governed by nutrient availability. Specific research interests include how animals acclimate to survive starvation, the mechanisms underlying adult consequences of early life starvation, the genetic basis of natural variation among wild strains, the function of conserved tumor suppressors, epigenetic effects of starvation, and how early life experience affects adult disease. The Baugh Lab's publication record demonstrates a consistent focus on nutrient signaling pathways, particularly involving insulin/IGF-1 signaling, PTEN, and Rb pathways. Recent work has expanded into environmental toxicology, examining how genetically diverse C. elegans strains respond to pollutants like PFAS. The research shows strong translational potential for understanding human metabolic diseases, developmental disorders, and responses to environmental stressors. Nutritional Control of Nematode Development (NIH 2025-2030) NSF-SNSF: Molecular Mechanism of a Life-History Tradeoff between Growth and Survival (NSF 2024-2027) Training Program in Developmental and Stem Cell Biology (NIH 2001-2027) Natural variation in C. elegans responses to environmental pollution (NIEHS 2023-2026) Dr. Baugh leads the Baugh Lab, which maintains an integrative organismal approach that considers molecular mechanisms in developmental and ecological contexts. The lab collaborates extensively with other research groups at Duke and internationally, particularly in the areas of genomic analysis and environmental toxicology.

• Phenotypic plasticity
• Developmental robustness
• Starvation adaptation
• +7 more

Rosalyn Ferguson is a University Teacher at the School of Allied Health Professions, Nursing and Midwifery, University of Sheffield, where she has taught Anatomy, Physiology, and Cell Biology across health-related programs since 2020. Her role encompasses curriculum leadership and pedagogical innovation in nursing and allied health education. Her academic credentials include: BSc Microbiology (Hons), University of Edinburgh MSc Clinical Medicine (Haematology), Queen’s University Belfast PhD in Cell Biology, Queen’s University Belfast Postgraduate Certificate in Education (PGCE), Queen’s University Belfast Dr. Ferguson's research centers on medical education pedagogy, with current projects standardizing Anatomy and Physiology teaching for nursing students and developing digital genomic medicine resources. She pioneers interactive software and online platforms to create flexible, cross-program educational materials that address critical gaps in allied health training. Her publication trajectory reveals a strategic shift from cancer biology (2010-2013), where she investigated metabolic disorder-cancer links through molecular mechanisms, to contemporary educational scholarship focused on quality assurance frameworks like the SAFE-A&P database. This evolution underscores her commitment to transforming healthcare education through evidence-based teaching standardization.

• Medical Education
• Anatomy and Physiology Education
• Genomic Medicine Education
• +3 more

Robert Clarke is a Professor of Breast Biology and Director of the Lobular Moon Shot Project at the Manchester Breast Centre, based at the Oglesby Cancer Research Building, University of Manchester. He leads research focused on breast cancer stem cells, metastasis, and prevention strategies. His work contributes to understanding cancer initiation and developing targeted therapies. Clarke holds a BSc (Hons) in Biology with European Studies (University of Sussex and Université Grenoble Alpes) and a PhD in Molecular Oncology from the University of Manchester (1995). His career includes postdoctoral training at The Christie NHS Foundation Trust and roles as a Cancer Research UK Research Fellow, Lecturer, and Reader before becoming a Professor. Research Interests: His lab investigates breast cancer stem cell regulation, hormonal influences on tumor development, and metastatic microenvironment modeling. Key themes include identifying self-renewal pathways for therapy and prevention strategies. He also explores circadian clock influences on cancer progression and chemoresistance mechanisms. Grants & Projects: Leading projects like Developing Targeted Strategies for Precision Breast Cancer Prevention and collaborating in initiatives such as the EurOPDX Consortium. He contributes to the NIHR Manchester Biomedical Research Centre and Cancer Manchester Research Centre . Teaching & Mentorship: Teaches Cancer Stem Cells to final-year Biology and Oncology students. Supervises PhD and postgraduate researchers, including those funded by Breast Cancer Now and MRC grants. His group includes over 15 researchers focused on breast cancer biology and therapy. Professional Engagement: Member of the Medical Research Council Clinical Training Panel, Swiss National Science Foundation, and editorial boards of Breast Cancer Research and Journal of Mammary Gland Biology and Neoplasia .

• Breast Cancer
• Cancer Stem Cells
• Metastasis
• +3 more

Michal Tomasz Marzec is an Associate Professor in the Department of Biomedical Sciences at the University of Copenhagen's Faculty of Health and Medical Sciences. His research focuses on protein folding mechanisms, particularly in the context of diabetes pathology and proinsulin handling. He leads a research group within the Inflammation, Metabolism and Oxidation section, with extensive collaborations across international institutions including the University of Michigan, Uppsala University, and Hannover Medical School. MD from Medical University of Warsaw (2000) PhD from Medical University of Bialystok (2011) Dr. Marzec's research centers on understanding protein folding processes, particularly wild-type protein folding which is highly relevant to patient conditions. His work has shifted from oncogenic pathways to investigating how organisms differ in disease susceptibility, with a current focus on diabetes pathology. He has made significant contributions in identifying GRP94 as an essential chaperone for proper proinsulin handling and is exploring links between genetic variability of protein chaperones and diabetes susceptibility. His publication record shows a strong focus on diabetes research, protein folding, and molecular mechanisms of disease, with numerous high-impact publications in journals such as Diabetes, PlosOne, and American Journal of Physiology. His research demonstrates consistent productivity with collaborations spanning multiple countries and institutions. EFSD/Lilly Programme grants for proinsulin folding research Magda Sofie og Aase Lütz Mindelegat Augustinus Fonden awards National Institute on Aging, NIH award DFF Marie Curie Mobilex fellowship Dr. Marzec serves as main supervisor for PhD students and has mentored numerous Master's and BA students from various international institutions. He has secured over 11 million DKK in research funding between 2011-2019. He is also actively involved in professional service as a member of the editorial board for journal Biology and as a reviewer for multiple prestigious journals including Diabetes, Blood, and Leukemia. His laboratory focuses on protein folding mechanisms with a technological platform specialized for disease-generic research applications. The lab currently includes a PhD student and three Master's students working on linked but separate projects.

• Protein folding
• Diabetes pathology
• Proinsulin handling
• +5 more

Carla Van Den Berg, Pharm.D. is an Associate Professor of Pharmacology & Toxicology at the University of Colorado Health Sciences Center, where she holds a tenured position in the School of Pharmacy, Department of Clinical Pharmacy. She also serves as Co-Director of the Developmental Therapeutics Lab at the Livestrong Cancer Institute and leads significant research in breast cancer molecular mechanisms. Dr. Van Den Berg earned her Doctor of Pharmacy from the University of Texas Health Science Center at San Antonio & University of Texas-Austin in 1991, following a Bachelor of Science in Pharmacy from the University of Colorado Boulder in 1989. Her post-doctoral training included a Clinical Oncology Residency at Audie Murphy VA Hospital and Oncology Research Fellowships at the Cancer Therapy & Research Center and University of Texas Health Sciences Center. Her laboratory research focuses on receptor tyrosine kinases (RTKs) and their role in breast, colon, lung, and prostate cancer. Specifically, she investigates JNK (c-Jun N-terminal Kinases) proteins and how they influence tumorigenesis, DNA damage, cell migration, and metastasis in breast cancer models. Her team has discovered that JNK proteins have diverse roles beyond cell death signaling, affecting mammary gland development, tumorigenesis, and response to chemotherapy. Using microarray technology, her lab has identified several genes through which JNKs influence cellular response to growth factors. Analysis of Dr. Van Den Berg's publication history reveals a strong focus on IGF-I signaling pathways and their relationship to chemotherapy resistance in breast cancer. Her work demonstrates how IGF-I rescues breast cancer cells from chemotherapy-induced cell death through proliferative and anti-apoptotic effects, and how JNK proteins interact with mTOR and other signaling molecules to regulate cancer cell behavior. Her research spans molecular mechanisms, preclinical models, and potential therapeutic applications. Professional Achievement Award, University of Colorado American College of Clinical Pharmacy-Cetus Oncology Research Award National Cancer Institute T-32 Research Training Grant Pharmacy Research Award, Post-Doctoral Training Programs, The University of Texas American College of Clinical Pharmacy-Rhone-Poulenc Rorer Research Award American Association of Colleges of Pharmacy New Investigator Award Dr. Van Den Berg has successfully secured over $1.8 million in research funding, including a $1 million National Cancer Institute grant for studying JNK in mammary gland development and tumorigenesis, a $206,340 Department of Defense grant on growth factor attenuation of cell death, and multiple awards from the Susan G. Komen Foundation. She has mentored numerous graduate students including Cindy Mamay (as thesis chair), Nancy Stolpman, Patrick Kerzic, Ileana Vargas, and Cathrine Denton, and has advised Pharm.D. students on oncology research projects. As Co-Director of the Developmental Therapeutics Lab at the Livestrong Cancer Institute, Dr. Van Den Berg leads a research team investigating molecular mechanisms of cancer progression and resistance to therapy. Her laboratory has made significant contributions to understanding how JNK proteins regulate breast cancer cell behavior and response to treatment, with potential implications for developing new therapeutic strategies targeting these pathways.

• Breast Cancer Research
• Molecular Oncology
• Pharmacology
• +3 more

John Perry is a Professor of Molecular Endocrinology at the University of Cambridge and an MRC Investigator at the MRC Epidemiology Unit. He co-leads the Early Life Aetiology and Mechanisms of Diabetes and Related Metabolic Disorders programme with Professor Ken Ong, focusing on human genetics approaches to understand links between early life growth, reproductive ageing, and later cardio-metabolic health. His work involves large-scale population studies and collaborations with researchers using animal and cellular models. Research Interests His research integrates genetic and epidemiological methods to explore: Genetic mechanisms of reproductive traits (puberty timing, menarche, menopause) Relationships between reproductive ageing and cardio-metabolic disease Role of hormonal pathways in metabolic health Translational applications of genetic findings for disease prevention Recent Article Trends Recent publications highlight genetic determinants of aging, obesity, cancer susceptibility, and neurodevelopmental processes. Key areas include proteomic aging, DNA repair pathways, cross-species obesity genetics, and functional genomics of reproductive traits using CRISPR and saturation editing techniques. Affiliations MRC Epidemiology Unit School of Clinical Medicine, University of Cambridge Cambridge Reproduction interdisciplinary network Cambridge Metabolic Network

• Population Genetics
• Reproductive Health
• Cardio-metabolic Disease
• +2 more

Prof. Abdu Adem is a Professor at the College of Medicine , Khalifa University , Abu Dhabi, with a career spanning over three decades. He previously served as a full Professor at the College of Medicine and Health Sciences, United Arab Emirates University (UAEU) from 1991 to 2020. Education : Ph.D. in Pharmacology (1987) from Uppsala University, Sweden; Docent title (Habilitation) from Karolinska Institute, Sweden (1991). Research Interests focus on neurodegeneration , particularly Alzheimer's disease, and diabetes biology , addressing its complications in the UAE population (24-28% prevalence). His work bridges neuroscience , pharmacology , and drug development . Article Trends highlight his expertise in anti-diabetic compounds (steroidal lactones, cycloheptylamine derivatives), neuroprotection (myrcene, valeric acid), and desert adaptation (camel physiology). Recent studies explore PPARγ activation , GLP-1 receptor agonists , and AGEs in diabetic complications . Scientific Awards : Sheikh Hamdan Award for Medical Sciences Nominated for Mohamed Bin Rashid Medal of Scientific Distinguishment Golden visa (10 years) by UAE Prime Minister Member of Mohamed Bin Rashid Academy of Scientists (MBRAS) Grants : Secured funding from European Union, Michael J. Fox Foundation, Sheikh Hamdan Bin Rashid Grant, UAEU, and Khalifa University. Labs/Teams : Leads research teams investigating neurodegeneration , diabetic complications , and camel physiology .

• Neuroscience
• Pharmacology
• Diabetes Research
• +3 more